
ab55341 at 1/100 staining human heart skeletal muscle sections (paraffin-embedded) by IHC-P. The image on the right has been treated with the synthesized phosphopeptide, image on the left is untreated.

ab55341 at 1/100 staining human heart (paraffin-embedded) using IHC. Image on right is treated with the synthesized phosphopeptide and the image on the left is untreated.

All lanes : Anti-IKK alpha + IKK beta (phospho S180 + S181) antibody (ab55341)Lane 1 : HepG2 cells treated with TNF (20 ng/ml, 5 mins)Lane 2 : HepG2 cells treated with TNF (20 ng/ml, 5 mins) with synthesized peptide